Geron Revenue Growth Rates (GERN), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Geron Corporation  (NASDAQ: GERN)
 

GERN's Revenue Growth by Quarter and Year

Geron's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

GERN Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 57.48
1st Quarter March 51.84
FY 109.32

GERNs Annual Revenue
Geron's Revenue in the fiscal year 2025 $ 183.62 millions
Geron's Revenue in the fiscal year 2024 $ 76.50 millions
Geron's Revenue in the fiscal year 2023 $ 0.24 millions
Geron's Revenue in the fiscal year 2022 $ 0.60 millions
Geron's Revenue in the fiscal year 2021 $ 1.39 millions




GERN Revenue second quarter 2026 Y/Y Growth Comment
Geron Corporation reported Revenue increase of 17.21% year on year in the second quarter 2026, to $ 57.48 millions, this is lower than Geron Corporation's recent average Revenue surge of 1545.91%.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 53 other companies have achieved higher Revenue growth. While Geron Corporation' s Revenue growth of 17.21% ranks overall at the positon no. 403 in the second quarter 2026.


GERN Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 1.53 % 235100 % -80 %
3rd Quarter September - 67.07 % 17568.75 % -46.67 %
2nd Quarter June 17.21 % 5472.73 % 2833.33 % -57.14 %
1st Quarter March 30.91 % 13100 % 1400 % -83.33 %
FY   - 140.07 % 33156.52 % -

Financial Statements
Geron's second quarter 2026 Revenue $ 57.48 millions GERN's Income Statement
Geron's second quarter 2025 Revenue $ 49.04 millions Quarterly GERN's Income Statement


GERN Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 1.12 % 66.4 % -87.5 %
3rd Quarter September - -3.69 % 3112.5 % 433.33 %
2nd Quarter June 10.88 % 23.84 % 193.33 % 50 %
1st Quarter March 8.54 % -15.82 % 1400 % -80 %
FY (Year on Year)   - 140.07 % 33156.52 % -


Back to GERN Growth rate Comparisons >> Back to GERN Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #54
Healthcare Sector #103
Overall #403

Revenue Y/Y Growth Statistics
High Average Low
32176.37 % 1545.91 % -85.78 %
(Dec 31 2024)   (Mar 31 2018)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #54
Healthcare Sector #103
Overall #403
Revenue Y/Y Growth Statistics
High Average Low
32176.37 % 1545.91 % -85.78 %
(Dec 31 2024)   (Mar 31 2018)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Geron's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
13988.84 % 382.57 % -99.38 %
(Sep 30 2015)  


GERN's II. Quarter Q/Q Revenue Comment
Geron Corporation achieved in the II. Quarter 2026 below company average Revenue rise of 10.88% quarter on quarter, to $ 57.48 millions.

Within Major Pharmaceutical Preparations industry 53 other companies have achieved higher Revenue quarter on quarter growth. While Geron's Revenue growth quarter on quarter, overall rank is 775.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #54
Healthcare Sector #124
Overall #775
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #54
Healthcare Sector #124
Overall #775
Revenue Q/Q Growth Statistics
High Average Low
13988.84 % 382.57 % -99.38 %
(Sep 30 2015)  


GERN's II. Quarter Q/Q Revenue Comment
Geron Corporation achieved in the II. Quarter 2026 below company average Revenue rise of 10.88% quarter on quarter, to $ 57.48 millions.

Within Major Pharmaceutical Preparations industry 53 other companies have achieved higher Revenue quarter on quarter growth. While Geron's Revenue growth quarter on quarter, overall rank is 775.


Geron's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 204.30 $ 195.86 $ 183.62 $ 182.90 $ 163.95
Y / Y Revenue Growth (TTM) 24.61 % 69.14 % 140.05 % 520.43 % 11840.86 %
Year on Year Revenue Growth Overall Ranking # 5 # 4 # 1 # 1 # 43
Seqeuential Revenue Change (TTM) 4.31 % 6.66 % 0.39 % 11.56 % 41.59 %
Seq. Revenue Growth (TTM) Overall Ranking # 404 # 235 # 34 # 8 # 55


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Geron's cumulative twelve months Revenue were $ 204 millions, company would post below average annual Revenue growth of 41.59% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Geron's Revenue growth from the 51.84% growth in Mar 31 2026.

Among companies within the Healthcare sector 2 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 4 to 5.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 54
Healthcare Sector # 3
Overall # 5

Revenue TTM Y/Y Growth Statistics
High Average Low
32176.37 %
 1545.91 %
-85.78 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 54
Sector # 102
S&P 500 # 404
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Geron's cumulative twelve months Revenue were $ 204 millions, company would post below average annual Revenue growth of -85.78% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Geron's Revenue growth from the 51.84% growth in Mar 31 2026.

Among companies within the Healthcare sector 2 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 4 to 5.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 54
Healthcare Sector # 3
Overall # 5

Revenue TTM Y/Y Growth Statistics
High Average Low
32176.37 %
1545.91 %
-85.78 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 54
Sector # 102
S&P 500 # 404




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
GERN's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue rise for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Personalis Inc 29.96%$ 29.960 millions
Beone Medicines Ltd 29.69%$ 29.693 millions
Capsovision Inc 29.60%$ 29.598 millions
Intuitive Surgical Inc 29.27%$ 29.272 millions
Xeris Biopharma Holdings Inc 28.74%$ 28.741 millions
Ultragenyx Pharmaceutical Inc 28.53%$ 28.532 millions
Innoviva Inc 28.39%$ 28.391 millions
Electrocore Inc 28.03%$ 28.031 millions
Lightwave Logic Inc 27.91%$ 27.909 millions
American Shared Hospital Services27.15%$ 27.149 millions
Protalix Biotherapeutics inc 27.07%$ 27.066 millions
Alkermes Plc 26.97%$ 26.968 millions
Lucid Diagnostics Inc 26.74%$ 26.741 millions
Lifestance Health Group Inc 26.08%$ 26.076 millions
Ani Pharmaceuticals Inc25.87%$ 25.866 millions
Sight Sciences Inc 25.83%$ 25.830 millions
Grail Inc 25.72%$ 25.723 millions
Fortress Biotech Inc 25.66%$ 25.658 millions
Apyx Medical Corp25.27%$ 25.273 millions
Radnet Inc 24.99%$ 24.986 millions
Precipio inc 24.18%$ 24.178 millions
Krystal Biotech Inc 24.14%$ 24.135 millions
Viemed Healthcare Inc 23.85%$ 23.853 millions
Ardelyx inc 23.77%$ 23.771 millions
Insulet Corporation23.51%$ 23.509 millions
Veracyte Inc 23.45%$ 23.448 millions
Journey Medical Corp23.33%$ 23.326 millions
Twist Bioscience Corporation23.24%$ 23.235 millions
Axogen inc 23.06%$ 23.065 millions
Vericel Corporation22.48%$ 22.481 millions


About Geron Revenue Growth Rates (GERN), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Geron Corp (CIK 886744).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0000886744-26-000037
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Geron Corp’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.